Revenue of $3.3 Million, a 12% Increase Compared to Prior Year ~~ Interim Analysis from MAINSAIL Study Reinforces Safety Profile, Effectiveness and Confirmation of Fusion ~~ Catamaran® SI Joint Fusion ...
Revenue of $3.3 Million, a 12% Increase Compared to Prior Year ~~ Interim Analysis from MAINSAIL Study Reinforces Safety Profile, Effectiveness and Confirmation of Fusion ~~ Catamaran® ...
Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome ...
Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback